We have previously reported that exogenous and endogenous estrogen can amplify residual cerebral blood flow during experimental cerebral ischemia. Because estrogen has been linked to nitric oxide and cyclic guanosine monophos phate (cGMP) signaling in noncerebral tissue, we tested the hypothesis that long-term 17!3-estradiol treatment increases basal cGMP in brain homogenates and cerebral microvessels in female rabbits. We also determined whether there are important baseline gender-specific differences in regional cGMP. Adult female rabbits were implanted with 17!3-estradiol pellets, 10 mg (FlO, n = 10) or 50 mg (F50, n = 13), and compared with untreated females (F, n = 19) and males with negligible es trogen (M, n = 19) (plasma 17!3-estradiol levels of 4 ± 4 pg/mL in M, 7 ± 5 pg/mL in F, 141 ± 74 pg/mL in FlO, and 289 ± 110 pg/mL in F50). Cyclic GMP was determined by radio immunoassay in cerebellum, hypothalamus, caudate nucleus, hippocampus, and cortex. Cerebral microvessels were har-
Women are at lower risk than men for cerebrovascular disease, including stroke and transient ischemic attack (Barret-Connor and Bush, 1991; Fisher et aI., 1965; Ford et aI., 1985; Sivenius et aI., 1991; Wolf et aI., 1987) , potentially owing to estrogen's enhancement of vascular function or possibly by direct neuroprotection. Estrogen is a known vasodilator of many regional circulations, and acute administration of 1713-estradiol increases blood flow to diverse brain areas (Goldman et aI., 1976) . How ever, it is unclear whether estrogens are important in regulation of CBF or tonic vasodilatory mechanisms. Es trogen has been linked to nitric oxide and cyclic guano-vested from additional cohorts of untreated males and females or estradiol-implanted females (n = 6 per group). Basal cGMP was higher in F versus M only in cerebellum. Estrogen-induced increases in regional cGMP were prominent in hippocampus at all doses (M = 43 ± 26, F = 43 ± 21, FlO = 84 ± 24, F50 = 117 ± 55 fmol/mg protein) and in cortex at the high dose (M = 78 ± 55, F = 88 ± 51, FlO = 69 ± 34, F50 = 143 ± 52 fmol/mg protein). Similarly, microvascular cGMP increased only in females treated with the 50 mg dose (M = 77 ± 13, F = 86 ± 25, FlO = 106 ± 35, F50 = 192 ± 88 fmol/mg protein). Therefore, 17!3-estradiol increases cGMP content in parenchymal regions that are known physiologic targets for reproductive steroids but are also areas of selective vulnerabil ity to ischemic insult. Further, high doses of estrogenic steroids could amplify cGMP signaling within the cerebral microvas culature. Key Words: Stroke-Estrogen-cGMP-Cerebral microvessels. sine monophosphate (cGMP) signaling in uterine tissue (Rosenfeld et aI., 1996; Weiner et aI., 1994) and the coronary circulation (Wellman et aI., 1996; White et aI., 1995) . Further, estrogenic steroids may employ cGMP dependent signal transduction pathways that are unre lated to nitric oxide (NO). Recent data suggest that estradiol relaxes coronary vessels in vitro by an endo thelium-independent mechanism involving cGMP dependent phosphorylation of large conductance, cal cium-activated K+ channels (White et aI., 1995) . The importance of cGMP in brain as a means of neuronal and vascular signaling is well known (Bredt and Snyder, 1989; Vallebuona and Raiteri, 1994) , although the im pact of estrogen on these signals is not known. Given the data that link estrogen to cGMP signaling in noncerebral tissue and our previous work implicating estrogen's va soactivity in brain (Hum et aI., 1995; Alkayed et aI., 1998) , we tested the hypothesis that increasing plasma levels of l713-estradiol in the female rabbit also increases basal cGMP in brain parenchyma and in cerebral micro vascular tissue. In addition, age-matched females and males with equivalently low levels of endogenous estro-gen were examined to determine the presence of inherent gender differences in regional cGMP.
METHODS
This study was approved by the Institutional Animal Care and Use Committee and is in compliance with the guidelines of the National Institutes of Health for care and handling of ani mals. Sexually mature female and male New Zealand rabbits (3 to 4 kg) were caged individually for a minimum period of 10 days under controlled light and temperature conditions. Four groups of animals were studied: (I) untreated females (F, n = 19 for tissue homogenates, n = 6 for cerebral microvessels), (2) females treated with 10 mg 17f3-estradiol pellets (FlO, n = 10 for homogenates, n = 6 for microvessels), (3) females treated with 50 mg 17f3-estradiol pellets (F50, n = 13 for homogenates, n = 6 for microvessels), and (4) untreated, age matched males (M, n = 19 for homogenates, n = 6 for mi crovessels). Untreated animals were sham-operated so that all groups received the same anesthetic exposure. In estrogen treated animals, a 17f3-estradiol pellet (Innovative Research, Toledo, OH, U.S.A.) was implanted subcutaneously on the dor sal neck surface (continuous release 2 !Lg/day, 21 days) I to 2 weeks before brain harvesting (Hum et aI., 1995) . In rabbit, endogenous estrogen production is suppressed when exogenous estradiol is administered, allowing control of plasma estradiol levels and eliminating the need for oophorectomy (Dharmara jan et a!., 199 1). Plasma 17f3-estradiol samples were obtained during tissue harvesting and measured by radioimmunoassay (Diagnostic Products Corp., Los Angeles, CA, U.S.A.) as pre viously described (Dharmarajan et aI., 1991) . All standards and samples were assayed in duplicate with interassay and intra assay variabilities of 4% and 7%, respectively (Dharmarajan et aI., 199 1; Hum et aI., 1995) .
For parenchymal cGMP measurements, the brain was har vested under deep barbiturate anesthesia with subsequent sub dissection on ice into five areas: cerebellum, hypothalamus, caudate nucleus, hippocampus, and the anterior and posteriolat eral cortex. The samples were frozen immediately in powdered dry ice and stored until assay at -80°C. For microvessel iso lation (Gebremedhin et aI., 1996) , each animal was anesthe tized with thiopental (100 to ISO mg) and mechanically venti lated while instrumented with a carotid artery catheter. After full-body perfusion through the left ventricle with cold HEPES buffered physiologic salt solution (PSS), 100 mL of ice-cold iron oxide solution (10 mg/mL, particle size 0. 15 !Lm, Aldrich Chemicals, Milwaukee, WI, U.S.A.) was injected through the carotid catheter. The brain was then harvested, surface pial vessels removed, and the cortex subdissected on ice. After mincing and passage through a 250-!Lm sieve (Cell Dissocia tion, Sieve-Fisher, Pittsburgh, PA, U.S.A.), iron-laden mi crovessels were separated from the parenchyma using a side pull magnet (Bio Mag Separator; Advanced Magnetics, Cam bridge, MA, U.S.A.). The retained tissue was resuspended in PSS with multiple repetitions of this magnetic separation. The crude microvessels were further separated by shearing through an 18-gauge needle, frozen in liquid nitrogen, and stored at -80°C for subsequent cGMP analysis. By light microscopy, the preparation appears as microvascular segments, predominantly vascular smooth muscle, with occasional adherent pericytes. To validate functional viability, we measured steady-state Na+-K+ ATPase activity as previously described (Fomitcheva and Kosk-Kosicka, 1996) . Enzyme activity was preserved in the microvascular preparation at 4.4 !Lm P/mg protein per hour.
Each sample was subsequently homogenized in PSS and precipitated with 6% trichloroacetic acid. After centrifugation, the resulting pellet was resuspended in I mollL NaOH, then 0.9 mollL HCI, and quantified for protein with the Coomassie blue technique (Pierce, Rockford, IL, U.S.A.) as previously de scribed (Pearce et aI., 1991) . The supernatants were washed with water-saturated ether, frozen in an ethanol/dry ice bath, then lyophilized for 12 to 72 hours. Cyclic GMP levels were measured in triplicate by commercial radioimmunoassay kit (Amersham Corp., Los Angeles, CA, U.S.A.) (Bredt and Snyder, 1989) and normalized relative to protein content (fmoll mg protein). lnterassay and intra-assay variability were each approximately 7%. The data were analyzed with one-way analysis of variance with a posthoc Newman-Keuls test to dis tinguish between treatment effects. Statistical significance was set at P < 0.05. All data are presented as mean ± SO.
RESULTS
Plasma 17 [3-estradiol levels at the time of tissue or microvessel harvesting were 4 ± 4 pg/mL in M, 7 ± 5 pg/mL in F, 141 ± 74 pg/mL in FlO, and 289 ± 110 pg/mL in F50. Cyclic GMP was comparable in all brain regions and the microvascular fraction of males and un treated females, with the exception of cerebellum (M = 76 ± 39 versus F = 136 ± 46 fmol/mg protein, P = 0.032) ( Fig. 1) . Estrogen increased tissue cGMP in the FlO group as compared with F in hippocampus (P = 0.0 11) and further increased cGMP in the high-dose group (P = 0.002). In addition, cortical cGMP content was higher in homogenates obtained from estrogen treated females as compared with F, but only at the high dose (F = 88 ± 51, FlO = 69 ± 34, F50 = 143 ± 52 fmol/mg protein, P = 0.042) (Fig. 2) . Similarly, cGMP in the microvessels isolated from hemispheric tissue was higher only in the F50 group (P < 0.002) relative to untreated females (Fig. 3 ).
DISCUSSION
The major findings in this study are that basal tissue cGMP levels in the female animal can be amplified in specific brain regions by long-term estrogen treatment and that the microvasculature is also responsive to ex ogenous steroid administration at high levels. Estrogen induced increases in tissue cGMP are most striking in regions that are physiologic, neuronal targets for female sex steroids and in regions with known vulnerability to ischemic injury, e.g., hippocampus and cortex. These findings suggest that one mechanism by which estro genic steroids act within brain is by amplifying regional cGMP signaling within the parenchyma and within small blood vessels. When brain cGMP content is compared in animals with low endogenous estrogen availability (un stimulated females and males), there are basal gender differences only in cerebellum.
We chose to quantify regional cGMP as one means of evaluating estrogen's potentially dual signaling targets in brain. There is evidence that estrogen can function as both a modulator of cerebral vasoreactivity (Hull et aI., 1992; Ohkura et aI., 1995) and of synaptic neurotrans mission, particularly in interaction with excitatory neu ronal activation (Woolley and McEwen, 1992; McEwen et aI., 1997; Woolley et aI., 1997) . Estradiol is a known vasodilator steroid in many circulations, including the cerebrovascular bed, under normal (Mendelsohn and Karas, 1994) and most clearly under pathologic condi tions (Hum et aI., 1995; Reis et aI., 1994; Williams et aI., 1994) . Fairly consistent results indicate that women have a higher mean hemispheric CBF as compared to men (Rodriguez et aI., 1988; Shaw et aI., 1984) and a greater homogeneity in regional flow distribution (Rodriguez et aI., 1988) . In a recent positron-emission tomographic study, estrogen administration enhanced regional CBF responses to cognitive activation in young women (Ber man et aI., 1997). Further, our laboratory and others have shown that estrogen alters vasodilatory capacity during J Cereh Blood Flow Me/ab, Vol. 18, No. 11. 1998 global cerebral ischemia (Hum et aI., 1995; Pelligrino et aI., 1996) .
Potential mechanisms by which estrogen could induce this vascular "plasticity" include hormonally enhanced release of NO and prostacyclin from vascular endothe lium (Mendelsohn and Karas, 1994) or cGMP-dependent vascular smooth muscle hyperpolarization (White et aI., 1995) . Therefore, we determined whether long-term es trogen treatment increased basal brain cGMP content, and inferentially, the potential capacity to alter cGMP signal transduction in blood vessels or surrounding neu ral tissue. Cyclic GMP is an important mediator of vas cular smooth muscle relaxation, as well as a critical el ement of many excitatory neurotransmitter systems in brain. Known cerebral vasodilators increase cGMP gen eration, including acetylcholine, substance P, and NO donors (Yu et aI., 1995) , and cell-permeable cGMP ana logs produce dilation of cerebral arterioles in situ (Pa terno et aI., 1996) . Our finding that cGMP content is elevated by 17�-estradiol is consistent with the observa tion that basal cGMP levels increase in ovine uterine artery during pregnancy (Magness et aI., 1991) . Both pregnancy and exogenous estradiol increase neuronal and endothelial NO synthase activity in uterine artery, heart, kidney, skeletal muscle, and cerebellum (Hayashi et aI., 1994; Weiner et aI., 1994) . Further, estrogen en hances both basal and stimulated NO release in isolated rat aorta under isometric conditions (Rahimian et aI., 1996) . In light of the estrogen-responsive elements within the promoter region of the NOS gene (Venema et aI., 1994) , it may be that estrogen increases cGMP con Effect of estrogen treatment on cGMP in isolated mi crovessels harvested from both cerebral hemispheres. Values represent means and SD from untreated female rabbits with en dogenous estrogen, untreated males with near zero plasma es trogen, and females treated with 10 mg or 50 mg of exogenous 17j3-estradiol (n = 6 per group). * P < 0.05 from female group. cerebellar cortex and hippocampus (Vallebuona and Raiteri, 1994; Luo et aI., 1994; East and Garthwaite, 1991) . However, cGMP is ubiquitous in the brain and increases may be linked to other NO-independent cellu lar processes. Recent data suggest that estradiol may act directly as a vasodilator by cGMP-dependent phosphor ylation of large conductance, calcium-activated K+ chan nels (White et aI., 1995) . Our data do not distinguish among these potential mechanisms but indicate that es trogen elevates cGMP content in tissue likely to be po tential targets for steroidal hormones.
Our measurements in rabbit indicate that microvascu lar cGMP is responsive only to high doses of exogenous estrogen. The high-dose pellet in the F50 group was cho sen to be consistent with the doses known to produce vasodilation in the rabbit during low blood flow condi tions (Hum et aI., 1995) . The lower dose in the FlO group yielded physiologic levels similar to those present with chorionic gonadotropin (hCG) -stimulated pseudo pregnancy in this species (Wu et aI., 1977) . This lower dose did not alter cGMP content compared with unstimu lated females with estrogen levels at the hormonal nadir, which may indicate that physiologic estrogen fluctuation does not alter vascular cGMP signaling. These data do not exclude possible cGMP induction in larger, upstream conductive and resistance vessels that greatly influence cerebral blood flow regulation under normal conditions. Nevertheless, it must be emphasized that exogenous es trogen augmentation can more than double basal cGMP availability in vascular tissue.
Cortical cGMP levels likewise responded to estrogen but only at supraphysiologic doses. In contrast, hippo campal cGMP content increased stepwise with increas ing estrogen doses, and the effect appeared to be region ally specific in that other noncortical regions such as caudate nucleus, hypothalamus, and cerebellum were un changed. Estrogen has a widespread group of cellular targets within brain (Stumpf, 1968) , and estrogen receptor mRNA-containing cells are present in many brain areas not generally associated with reproductive function (Simerly et aI., 1990) . The location of the es trogen-cGMP interaction is consistent with previous work showing histologic and functional hippocampal sensitivity to estrogen over a range of concentrations (McEwen et aI., 1997; Woolley et aI., 1997) . Estrogen can directly alter synaptic function in the CAl region for hours, as evidenced by alterations in dendritic spine den sity during the estrous cycle and in response to pharma cologically amplified estradiol (Woolley and McEwen, 1992) . In addition, although the regional and cellular estrogen receptor profile of the f3-receptor SUbtype is still unclear at present, immunocytochemical localization of classic estrogen receptors, likely a-subtype, on hippo campal intemeurons has been documented (Weiland et aI., 1996) .
What remains to be shown is whether, and under what conditions, estrogen-mediated increases in cGMP con tent alter functional signaling in the cortex or hippocam pus. Because these brain regions are known for their vulnerability to ischemic insult, one potential conse quence may be to alter neuronal cell viability and loss.
Endogenous estrogen provides substantial neuroprotec tion from carotid artery occlusion in the gerbil (Hall et aI., 1991) and salvages cortical and striatal tissue after middle cerebral artery occlusion in rat, as does long-term estradiol treatment in ovariectomized female rodents (Alkayed et aI., 1998; Rusa et aI., 1998) . The present data do not address the functional significance of estrogen's effect on cortical or hippocampal cGMP levels or estab lish a link to mechanisms of ischemic cell injury. Nev ertheless, the regional specificity of estrogen's cGMP amplification is striking, particularly given the evidence that estrogen protects ischemic brain in several experi mental stroke models.
In conclusion, estrogenic steroids likely employ mul tiple signaling mechanisms to alter neuronal and vascular physiology in brain. The present study demonstrates that long-term treatment with 17f3-estradiol, the principal biologically active estrogen in mammals, increases cGMP content in a selective and dose-specific manner.
Therefore, we hypothesize that long-term exposure to high estrogen results in augmented basal cGMP with a consequently greater sensitivity to cGMP-transduced va sodilatory and neural stimuli.
